Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel Monkeys
- 1 October 1990
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 13 (5) , 448-458
- https://doi.org/10.1097/00002826-199010000-00006
Abstract
We examined the ability of L-DOPA to induce dyskinesias in MPTP-treated and normal squirrel monkeys to establish whether the underlying neuropathology associated with parkinsonism is an absolute requirement or merely promotes the development of drug-induced dyskinesias. Administration of L-DOPA (5-40 mg/kg p.o., following a 60 min pretreatment with carbidopa 2.5-20 mg/kg p.o.) induced a range of dopamine-mediated behaviors including locomotor activity, stereotyped scratching, and climbing in both lesioned and nonlesioned animals. However, the dose-response curves showed a marked (three- to fourfold) shift to the left in lesioned animals, indicating behavioral supersensitivity. In contrast, L-DOPA-induced dyskinesias were only observed in MPTP-treated monkeys. Doses required for induction of dyskinesias were lower than those required to induce climbing. These findings provide further evidence that nigrostriatal damage is essential for the genesis of L-DOPA-induced dyskinesias.This publication has 11 references indexed in Scilit:
- Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damagePharmacology Biochemistry and Behavior, 1989
- Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned ratsJournal of Neuroscience, 1989
- Does levodopa aggravate Parkinson's disease?Neurology, 1988
- Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turningEuropean Journal of Pharmacology, 1987
- Long‐term follow‐up of early dopa treatment in Parkinson's diseaseAnnals of Neurology, 1986
- (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISMThe Lancet, 1985
- Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)Neurology, 1985
- Carbamazepine‐induced orofacial dyskinesiaNeurology, 1980
- Relationship between tardive dyskinesia, l-Dopa-induced hyperkinesia and parkinsonismPsychopharmacology, 1977
- Oral Facial Dyskinesia Associated with Prolonged Use of Antihistaminic DecongestantsNew England Journal of Medicine, 1975